The effects of L-threo-3,4-dihydroxyphenylserine on the total norepinephrine and dopamine concentrations in the cerebrospinal fluid and freezing gait in parkinsonian patients

  • H. Tohgi
  • T. Abe
  • S. Takahashi
Full Papers


We studied the effects of L-threo-DOPS (L-DOPS) on the concentrations of total (conjugated and unconjugated) dopamine (DA) and norepinephrine (NE) in the cerebrospinal fluid (CSF) of parkinsonian patients with freezing phenomenon. The NE concentration increased remarkably and dose-dependently after administration of L-DOPS in both L-dopa/carbidopa-pretreated and untreated patients. The DA concentration also increased mildly but significantly in L-dopa/carbidopa-untreated patients. Freezing phenomenon improved in 6 out of 8 patients at Hoehn and Yahr's stage III, and 1 out of 5 patients at stage IV. These results indicate that L-DOPS administration increases the NE concentration dosedependently, and is effective for freezing of gait of moderate severity.


L-threo-DOPS freezing of gait norepinephrine dopamine cerebrospinal fluid 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Andén N, Grabowska M (1976) Pharmacological evidence for a stimulation of dopamine neurons by noradrenaline neurons in the brain. Eur J Pharmacol 39: 275–282CrossRefPubMedGoogle Scholar
  2. Brannan T, Bhardwaj A, Yahr MD (1990) L-threodops increases extracellular norepinephrine levels in the brain: an in vivo study. Neurology 40: 1134–1135PubMedGoogle Scholar
  3. Corrodi H, Fuxe K, Ljungdahl Å, Ögren SO (1970) Studies on the action of some psychoactive drugs on central noradrenaline neurones after inhibition of dopamine-β-hydroxylase. Brain Res 24: 451–470CrossRefPubMedGoogle Scholar
  4. Edwards DJ, Rizk M (1981) Effects of amino acid precursors on catecholamine synthesis in the brain. Prog Neuro-Psychopharmacol 5: 569–572CrossRefGoogle Scholar
  5. Edwards DJ, Sedlock ML (1982) Increased brain concentration of homovanillic acid in rats treated with threo-3,4-dihydroxyphenylserine. J Pharm Pharmacol 34: 685–686PubMedGoogle Scholar
  6. Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17: 427–442PubMedGoogle Scholar
  7. Inagaki C, Fujiwara H, Tanaka C (1976) Inhibitory effect of (+)-threo-3,4-dihydroxyphenylserine (DOPS) on decarboxylation of (−)-threo-DOPS. Jpn J Pharmacol 26: 380–382PubMedGoogle Scholar
  8. Lieberman A, Dziatolowski M, Gopinathan G, Kupersmith M, Neophytides A, Korein J (1980) Evaluation of Parkinson's disease. In: Goldstein M, Calne DB, Lieberman AN, Thorner MO (eds) Ergot compounds and brain function: neuroendocrine and neuropsychiatric aspects. Raven Press, New York, pp 277–286Google Scholar
  9. Nagatsu T, Kato T, Numata Y, Ikuta K, Sano M, Nagatsu I, Kondo Y, Inagaki S, Iizuka R, Hori A, Narabayashi H (1977) Phenylethanoamine N-methyl-transferase and other enzymes of catecholamine metabolism in human brain. Clin Chim Acta 75: 221–232CrossRefPubMedGoogle Scholar
  10. Nagatsu T, Kato T, Nagatsu I, Kondo Y, Inagaki S, Iizuka R, Narabayashi H (1979) Catecholamine related enzymes in the brain of patients with parkinsonism and Wilson's disease. Adv Neurol 24: 283–292Google Scholar
  11. Nagatsu T, Wakui Y, Kato T, Fujita K, Kondo T, Yokochi F, Narabayashi H (1982) Dopamine beta-hydroxylase activity in cerebrospinal fluid of Parkinsonian patients. Biomed Res 3: 95–98Google Scholar
  12. Narabayashi H, Kondo T (1987) Results of a double-blind study of L-threo-DOPS in parkinsonism. In: Fahn S, et al (eds) Recent developments in Parkinson's disease, vol II. Macmillan, New Jersey, pp 279–291Google Scholar
  13. Narabayashi H, Kondo T, Hayashi A, Suzuki T, Nagatsu T (1981) L-threo-3,4-dihydroxyphenylserine treatment for akinesia and freezing of parkinsonism. Proc Jpn Acad 57 (Ser B): 351–354Google Scholar
  14. Pycock CJ, Donaldson IM, Marsden CD (1975) Circling behavior produced by unilateral lesions in the region on the locus coeruleus in rats. Brain Res 97: 317–329CrossRefPubMedGoogle Scholar
  15. Quinn NP, Luthert P, Honavar M, Marsden CD (1989) Pure akinesia due to Lewy body Parkinson's disease: a case with pathology. Mov Disord 4: 85–89CrossRefPubMedGoogle Scholar
  16. Suzuki T, Sakoda S, Ueji M, Kishimoto S, Hayashi A, Kondo T, Narabayashi H (1984) Treatment of parkinsonism with L-threo-3,4-dihydroxyphenylserine: a pharmacokinetic study. Neurology 34: 1446–1450PubMedGoogle Scholar
  17. Tohgi H, Abe T, Takahashi S, Ueno M, Nozaki Y (1990) Cerebrospinal fluid dopamine, norepinephrine, and epinephrine concentrations in Parkinson's disease correlated with clinical symptoms. Adv Neurol 53: 277–282PubMedGoogle Scholar
  18. Tohgi H, Abe T, Takahashi S, Takahashi J, Ueno M, Nozaki Y (1990) Effect of a synthetic norepinephrine precursor, L-threo-3,4-dihydroxyphenylserine on the total norepinephrine concentration in the cerebrospinal fluid of parkinsonian patients. Neurosci Lett 116: 194–197CrossRefPubMedGoogle Scholar
  19. Tohgi H, Abe S, Takahashi S, Takahashi J, Nozaki Y, Ueno M, Kikuchi T (1993) Monoamine metabolism in the cerebrospinal fluid in Parkinson's disease: relationship to clinical symptoms and subsequent therapeutic outcomes. J Neural Transm [P-D Sect] 5: 17–26Google Scholar
  20. Tyce GM, Rorie DK, Byer DE, Danielson DR (1985) Free anol conjugated amines in human lumbar cerebrospinal fluid. J Neurochem 44: 322–324PubMedGoogle Scholar
  21. Yamamoto M, Ogawa N, Ujike H (1986) Effect of L-threo-3,4-dihydroxyphenylserine chronic administration on cerebrospinal fluid and plasma free 3-methoxy-4-hydroxy-phenylglycol concentration in patients with Parkinson's disease. J Neurol Sci 73: 39–44CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • H. Tohgi
    • 1
  • T. Abe
    • 1
  • S. Takahashi
    • 1
  1. 1.Department of NeurologyIwate Medical UniversityMoriokaJapan

Personalised recommendations